A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD

This is a phase 2a, multicenter, randomized, double-blind, single-dummy, positive drug and placebo-controlled, parallel group study to evaluate the safety and efficacy of Hemay005 in adults with moderate to severe chronic obstructive pulmonary disease (COPD). Subjects will receive Hemay005 twice daily, or placebo, or positive drug roflumilast with a maximum treatment duration of 12 weeks. The study also includes an off-treatment safety follow-up period of 4 weeks.